SCHEMBL6701140

SCHEMBL6701140

CN1C(=O)N(Cc2ccccc2)Cc2cc(C(=O)O)oc21

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.42
CYP2D6 P10635 1/20 0.42
CYP2C9 P11712 1/20 0.42
CYP2C19 P33261 1/20 0.42
KMT2A Q03164 1/20 0.42
DRD3 P35462 1/20 0.41
KCNH2 Q12809 1/20 0.41
PARP1 P09874 1/20 0.41
HDAC6 Q9UBN7 2/20 0.39
CACNA1G O43497 2/20 0.38
CACNA1H O95180 2/20 0.38
CACNA1I Q9P0X4 2/20 0.38
PREP P48147 1/20 0.38
HDAC4 P56524 1/20 0.38
HDAC1 Q13547 1/20 0.38
CASP3 P42574 1/20 0.37
ENPP2 Q13822 2/20 0.37
S1PR2 O95136 1/20 0.37
BRD4 O60885 1/20 0.36
KDM4E B2RXH2 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6697984 0.84 ALDH1A1 (0.36) CACNA1GCACNA1HCACNA1IALDH1A1
SCHEMBL6694967 0.79 MMP13 (0.46) POLBCYP2D6CYP2C9CYP2C19KMT2A
SCHEMBL6699545 0.73 MMP13 (0.39) POLBDRD3KCNH2ALDH1A1TDP1
SCHEMBL7212064 0.73 ENPP2 (0.53) POLBCYP2D6CYP2C9CYP2C19KMT2A
SCHEMBL3598510 0.70 DRD3 (0.42) POLBCYP2D6CYP2C9CYP2C19KMT2A
SCHEMBL6696978 0.70 PTGER4 (0.46) HDAC6ALDH1A1
SCHEMBL11605657 0.69 ELANE (0.50) POLBCYP2D6CYP2C9CYP2C19KMT2A
SCHEMBL6288755 0.69 TP53 (0.45) POLBHDAC6ALDH1A1
SCHEMBL13545313 0.68 NR3C1 (0.48) POLBCYP2D6CYP2C9CYP2C19KMT2A
SCHEMBL6703290 0.68 MMP13 (0.43) HDAC6HDAC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2004014916-A1 PYRIMIDINE FUSED BICYCLIC METALLOPROTEINASE INHIBITORS WARNER-LAMBERT COMPANY LLC (US) 2004-02-19 WO claimed
US-20040038994-A1 Pyrimidine fused bicyclic metalloproteinase inhibitors WILSON MICHAEL WILLIAM (US) 2004-02-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040038994-A1 Pyrimidine fused bicyclic metalloproteinase inhibitors MMP9, MMP1, MMP2 POLB 678/4885CYP2D6 729/4885CYP2C9 634/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.